IL322741A - Antisense oligomer formulations - Google Patents

Antisense oligomer formulations

Info

Publication number
IL322741A
IL322741A IL322741A IL32274125A IL322741A IL 322741 A IL322741 A IL 322741A IL 322741 A IL322741 A IL 322741A IL 32274125 A IL32274125 A IL 32274125A IL 322741 A IL322741 A IL 322741A
Authority
IL
Israel
Prior art keywords
pharmaceutical formulation
aso
liquid composition
kit
concentration
Prior art date
Application number
IL322741A
Other languages
English (en)
Hebrew (he)
Original Assignee
Stoke Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stoke Therapeutics Inc filed Critical Stoke Therapeutics Inc
Publication of IL322741A publication Critical patent/IL322741A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL322741A 2023-02-14 2024-02-14 Antisense oligomer formulations IL322741A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363484890P 2023-02-14 2023-02-14
US202463625171P 2024-01-25 2024-01-25
PCT/US2024/015838 WO2024173582A2 (en) 2023-02-14 2024-02-14 Antisense oligomer formulations

Publications (1)

Publication Number Publication Date
IL322741A true IL322741A (en) 2025-10-01

Family

ID=92420749

Family Applications (1)

Application Number Title Priority Date Filing Date
IL322741A IL322741A (en) 2023-02-14 2024-02-14 Antisense oligomer formulations

Country Status (8)

Country Link
EP (1) EP4665407A2 (de)
JP (1) JP2026507323A (de)
KR (1) KR20250155076A (de)
CN (1) CN121194802A (de)
AU (1) AU2024222908A1 (de)
IL (1) IL322741A (de)
MX (1) MX2025009526A (de)
WO (1) WO2024173582A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113748209A (zh) 2019-02-27 2021-12-03 斯托克制药公司 用于治疗病况和疾病的反义寡聚体
KR20230022409A (ko) 2020-05-11 2023-02-15 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2447052A1 (en) * 2001-05-17 2002-11-21 Avi Biopharma, Inc. Combined approach to treatment of cancer using a c-myc antisense oligomer
CA3101321A1 (en) * 2018-06-26 2020-01-02 Nippon Shinyaku Co., Ltd. Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy
IL293531A (en) * 2019-12-06 2022-08-01 Stoke Therapeutics Inc Antisense oligomers for the treatment of conditions and diseases

Also Published As

Publication number Publication date
MX2025009526A (es) 2025-11-03
WO2024173582A3 (en) 2024-10-03
EP4665407A2 (de) 2025-12-24
KR20250155076A (ko) 2025-10-29
WO2024173582A2 (en) 2024-08-22
AU2024222908A1 (en) 2025-09-04
JP2026507323A (ja) 2026-03-02
CN121194802A (zh) 2025-12-23

Similar Documents

Publication Publication Date Title
US20230116704A1 (en) Antisense oligomers for treatment of conditions and diseases
US20250243493A1 (en) Compounds for treatment of conditions and diseases
US6653466B2 (en) Pharmaceutical composition for treatment of duchenne muscular dystrophy
AU780517B2 (en) Medicament for treatment of duchenne muscular dystrophy
US11034962B2 (en) Inhibitors of CACNA1A/ALPHA1A subunit internal ribosomal entry site (IRES) and methods of treating spinocerebellar ataxia type 6
GB2594767A (en) Antisense oligomers for treatment of conditions and diseases
JP2019500346A (ja) 腎臓病の処置のための組成物と方法
KR20220084437A (ko) 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
WO2024173582A2 (en) Antisense oligomer formulations
JP2002325582A (ja) デュシェンヌ型筋ジストロフィー治療剤
US20250066781A1 (en) Methods for treating conditions and diseases
WO2025199503A1 (en) Methods for treating conditions and diseases
WO2025024568A1 (en) Methods for treating conditions and diseases
JP2025519571A (ja) 一遺伝子性神経発達障害の治療のための組成物及び方法
AU2023329830A1 (en) Engineered constructs for increased transcription of rna payloads
US20250283086A1 (en) Compositions and methods for treatment of kidney disease
HK40064034A (en) Antisense oligomers for treatment of conditions and diseases